Combining immunotherapy with radiation therapy to induce the abscopal response: What clinical and treatment variables matter?

Description This review article identifies demographic, clinical, and treatment variables associated with the abscopal effect— the phenomenon in which radiation induces a regression of tumor cells outside the field of irradiation. Authors describe the current state of knowledge regarding these variables and examine research on the influence of tumor type, patient’s immune system, overall tumor burden, and radiation therapy parameters on the abscopal effect.

[1]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[2]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[3]  I. Melero,et al.  Radiation effects on antitumor immune responses: current perspectives and challenges , 2018, Therapeutic advances in medical oncology.

[4]  C. Belka,et al.  Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences , 2017, Immunological reviews.

[5]  K. Patel,et al.  Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases , 2017, American journal of clinical oncology.

[6]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[7]  R. Neves,et al.  Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab , 2017, Journal of Radiation Oncology.

[8]  Laurentiu M. Pop,et al.  Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment , 2017, Cancer Immunology, Immunotherapy.

[9]  Lidia Strigari,et al.  A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? , 2017, PloS one.

[10]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[11]  R. Neves,et al.  Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone , 2017, Cancer biology & therapy.

[12]  Ludmila V. Danilova,et al.  Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[13]  Ludmila V. Danilova,et al.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[14]  G. Robertson,et al.  Malignant melanoma-The cradle of anti-neoplastic immunotherapy. , 2016, Critical reviews in oncology/hematology.

[15]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[16]  Rosie Qin,et al.  Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. , 2016, International journal of radiation oncology, biology, physics.

[17]  T. Schmid,et al.  Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma , 2016, Cancer Immunology Research.

[18]  U. Ricardi,et al.  Radiotherapy and immune checkpoints inhibitors for advanced melanoma. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  H. Kohrt,et al.  In situ vaccination for the treatment of cancer. , 2016, Immunotherapy.

[20]  S. Demaria,et al.  In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. , 2015, Vaccine.

[21]  Michael R Hamblin,et al.  Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death , 2015, Front. Immunol..

[22]  G. Gibney,et al.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  S. Swetter,et al.  A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. , 2015, International journal of radiation oncology, biology, physics.

[24]  Rainer Fietkau,et al.  Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications , 2015, Front. Immunol..

[25]  C. Drake,et al.  Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.

[26]  Jinming Yu,et al.  Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. , 2015, Cancer letters.

[27]  S. Demaria,et al.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.

[28]  H. Kohrt,et al.  In-situ tumor vaccination: Bringing the fight to the tumor , 2015, Human vaccines & immunotherapeutics.

[29]  Y. Yamada,et al.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.

[30]  Joe Y. Chang,et al.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.

[31]  J. Kirkwood,et al.  Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. , 2014, JAMA.

[32]  K. Shirai,et al.  Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery , 2014, Cancer medicine.

[33]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[34]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[35]  C. Barker,et al.  Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. , 2014, International journal of radiation oncology, biology, physics.

[36]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy. , 2014, Current opinion in immunology.

[37]  Brady T. West,et al.  Ipilimumab and radiation therapy for melanoma brain metastases , 2013, Cancer medicine.

[38]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[39]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[40]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[41]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[42]  S. Grossman,et al.  Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. , 2012, CNS oncology.

[43]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[44]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[45]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[46]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[47]  Chung-Pin Li,et al.  Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma , 2005, Journal of immunotherapy.

[48]  M. Akiyama,et al.  Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. , 1990, Radiation research.

[49]  L. Lu,et al.  A comparison of lung metastases and natural killer cell activity in daily fractions and weekly fractions of radiation therapy on murine B16a melanoma. , 1988, Radiation research.

[50]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .

[51]  E. Golden,et al.  Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.

[52]  Patrizia Agostinis,et al.  Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. , 2010, Biochimica et biophysica acta.